Caricamento...

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma

Cancer cells escape immune recognition by exploiting the programmed cell-death protein 1 (PD-1)/programmed cell-death 1 ligand 1 (PD-L1) immune checkpoint axis. Immune checkpoint inhibitors that target PD-1/PD-L1 unleash the properties of effector T cells that are licensed to kill cancer cells. Immu...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunol Res
Autori principali: Apostolidis, John, Sayyed, Ayman, Darweesh, Mohammed, Kaloyannidis, Panayotis, Al Hashmi, Hani
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7647776/
https://ncbi.nlm.nih.gov/pubmed/33178841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/9350272
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !